Pancreatic Cancer Research

ResearcherBC Cancer AgencyActive in the last 2 years

Steve E. Kalloger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1332-7881; OpenAlex author ID A5085580353. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 6 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 20

  1. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  2. Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles. Co-author DOI 10.1186/s40170-024-00357-z↗
  3. Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1242/jcs.260644↗
  4. Classification of Pancreatic Ductal Adenocarcinoma Using MALDI Mass Spectrometry Imaging Combined with Neural Networks. Co-author DOI 10.3390/cancers15030686↗
  5. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  6. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3695↗
  7. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33304↗
  8. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Co-author DOI 10.1007/s00428-020-02987-2↗
  9. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  10. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  11. Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Co-author DOI 10.1177/11772719211049852↗
  12. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Co-author DOI 10.1002/cam4.2973↗
  13. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1543↗
  14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Co-author DOI 10.1053/j.gastro.2019.05.004↗
  15. Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Co-author DOI 10.1101/mcs.a003681↗
  16. Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorour… Co-author DOI 10.1200/po.18.00057↗
  17. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated w… Co-author DOI 10.1002/cjp2.75↗
  18. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12885-017-3634-5↗
  19. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. First author DOI 10.1038/modpathol.2015.89↗
  20. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Co-author DOI 10.1038/nm.3973↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David F. Schaeffer · 20 shared papers, 2015–2025 · strength 2.11
  2. Daniel John Renouf · 18 shared papers, 2015–2025 · strength 1.78
  3. Joanna M. Karasinska · 14 shared papers, 2017–2025 · strength 1.47
  4. James Thomas Topham · 9 shared papers, 2019–2025 · strength 1.03
  5. Janessa J. Laskin · 8 shared papers, 2018–2025 · strength 0.79
  6. Hui‐Li Wong · 8 shared papers, 2017–2022 · strength 0.69
  7. Steve Gallinger · 6 shared papers, 2015–2025 · strength 0.59
  8. Grainne Mary O'Kane · 5 shared papers, 2020–2025 · strength 0.55
  9. Jennifer Jane Knox · 5 shared papers, 2020–2025 · strength 0.55
  10. Faiyaz Notta · 5 shared papers, 2020–2025 · strength 0.55
  11. Rachel Anne Goodwin · 4 shared papers, 2021–2025 · strength 0.47
  12. Oliver F. Bathe · 4 shared papers, 2021–2025 · strength 0.47
  13. Michael K.C. Lee · 5 shared papers, 2020–2021 · strength 0.47
  14. Hassan A. Ali · 3 shared papers, 2022–2025 · strength 0.46
  15. Erica S. Tsang · 3 shared papers, 2021–2022 · strength 0.29
  16. Paul C. McDonald · 2 shared papers, 2019–2024 · strength 0.25
  17. Shoukat Dedhar · 2 shared papers, 2019–2024 · strength 0.25
  18. Kasmintan A. Schrader · 3 shared papers, 2018–2020 · strength 0.21
  19. Frederic Kanter · 1 shared paper, 2023 · strength 0.20
  20. Oliver Klein · 1 shared paper, 2023 · strength 0.20
  21. Seth J. Parker · 1 shared paper, 2024 · strength 0.18
  22. Lan Valerie Tao · 1 shared paper, 2024 · strength 0.18
  23. Paalini Sathiyaseelan · 1 shared paper, 2023 · strength 0.15
  24. Sharon M. Gorski · 1 shared paper, 2023 · strength 0.15
  25. Carol Cremin · 2 shared papers, 2019–2020 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.